Stem Cells International

Research Article

Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

Table 1

Features of the patients.


	Patient #1 (59/M)	Patient #2 (30/F)

KT age	44	24
Primary renal disease	HTN	MPGN
Comorbid disease	DM	HTN
Time between KT and MSC Tx	15 years 4 months	5 years 4 months
Height (cm)/weight (kg)/BMI (kg/m²) at time of MSC Tx	175.2/66.8/21.8	166.7/77.5/27.9
KDPI score	Unknown	-9
Donor age	23	31
Donor sex	Male	Male
Donor type	Deceased	Living
DSA	Unknown, but multiple strong DQs	Non-DSA with strong MFI in DQ
Previous AMR Tx	2 times	3 times
Time after last AMR Tx	4 months	2 months
Banff lesion scores for CAMR	G1 T0 I2 V0 AH3 PTC3 TI2 AAH3	G3 T1 I1 V0 AH0 PTC3 TI2 AAH0
Banff lesion scores for CAMR	CG3 CT1 CI1 CV0 MM1 C4d3 i-IFTA1	CG3 CT1 CI1 CV0 MM1 C4d2 i-IFTA1

KT: kidney transplantation; HTN: hypertension; MPGN: membranoproliferative glomerulonephritis; DM: diabetes mellitus; MSC: mesenchymal stem cell; Tx: treatment; KDPI: kidney donor profile index; DSA: donor-specific antibody; AMR: antibody-mediated rejection; CAMR: chronic active antibody-mediated rejection; G: glomerulitis; T: tubulitis; I: interstitial inflammation; V: intimal arteritis; AH: arteriolar hyalinosis; PTC: peritubular capillaritis; TI: total inflammation; AAH: hyaline arteriolar thickening; CG: glomerular basement membrane double contours; CT: tubular atrophy; CI: interstitial fibrosis; CV: vascular fibrous intimal thickening; MM: mesangial matrix expansion; i-IFTA: inflammation in area of interstitial fibrosis and tubular atrophy.